Terms: = Brain cancer AND CEP17 AND Treatment
4 results:
1. Advanced lung adenocarcinoma with coexistent HER2 mutation and amplification and response to afatinib: a case report.
Liu X; Cao Y; Li Y; Duan X
Ann Palliat Med; 2020 Mar; 9(2):483-487. PubMed ID: 32075402
[TBL] [Abstract] [Full Text] [Related]
2. Actionability of HER2-amplified circulating tumor cells in HER2-negative metastatic breast cancer: the CirCe T-DM1 trial.
Jacot W; Cottu P; Berger F; Dubot C; Venat-Bouvet L; Lortholary A; Bourgeois H; Bollet M; Servent V; Luporsi E; Espié M; Guiu S; D'Hondt V; Dieras V; Sablin MP; Brain E; Neffati S; Pierga JY; Bidard FC
Breast Cancer Res; 2019 Nov; 21(1):121. PubMed ID: 31727113
[TBL] [Abstract] [Full Text] [Related]
3. cancer Signature Investigation: ERBB2 (HER2)-Activating Mutation and Amplification-Positive Breast Carcinoma Mimicking Lung Primary.
Shih J; Bashir B; Gustafson KS; Andrake M; Dunbrack RL; Goldstein LJ; Boumber Y
J Natl Compr Canc Netw; 2015 Aug; 13(8):947-52. PubMed ID: 26285240
[TBL] [Abstract] [Full Text] [Related]
4. Correlation between quantitative HER-2 protein expression and risk for brain metastases in HER-2+ advanced breast cancer patients receiving trastuzumab-containing therapy.
Duchnowska R; Biernat W; Szostakiewicz B; Sperinde J; Piette F; Haddad M; Paquet A; Lie Y; Czartoryska-Arłukowicz B; Wysocki P; Jankowski T; Radecka B; Foszczynska-Kłoda M; Litwiniuk M; Debska S; Weidler J; Huang W; Buyse M; Bates M; Jassem J
Oncologist; 2012; 17(1):26-35. PubMed ID: 22234627
[TBL] [Abstract] [Full Text] [Related]
